LMAT Stock Overview
Develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
LeMaitre Vascular, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$80.09 |
52 Week High | US$81.68 |
52 Week Low | US$44.27 |
Beta | 0.89 |
1 Month Change | 2.59% |
3 Month Change | 19.82% |
1 Year Change | 19.79% |
3 Year Change | 30.00% |
5 Year Change | 189.24% |
Change since IPO | 1,191.77% |
Recent News & Updates
Recent updates
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
Jun 05LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
May 02Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
Apr 04Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Feb 29What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jan 19Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture
Oct 27Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Oct 11Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?
Aug 30The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence
Jul 06Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?
May 20Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Mar 12Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Oct 23Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Oct 05LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital
Sep 13LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers
Sep 08LeMaitre Vascular goes ex dividend tomorrow
Aug 23LeMaitre Vascular: 16% Return Objective From Idiosyncratic Risk Premia
Jun 24What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jun 15Are Investors Undervaluing LeMaitre Vascular, Inc. (NASDAQ:LMAT) By 40%?
May 06Shareholder Returns
LMAT | US Medical Equipment | US Market | |
---|---|---|---|
7D | 3.4% | -1.2% | 1.2% |
1Y | 19.8% | -1.0% | 20.6% |
Return vs Industry: LMAT exceeded the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: LMAT matched the US Market which returned 20.5% over the past year.
Price Volatility
LMAT volatility | |
---|---|
LMAT Average Weekly Movement | 4.5% |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LMAT has not had significant price volatility in the past 3 months.
Volatility Over Time: LMAT's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | 622 | George LeMaitre | www.lemaitre.com |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries.
LeMaitre Vascular, Inc. Fundamentals Summary
LMAT fundamental statistics | |
---|---|
Market cap | US$1.77b |
Earnings (TTM) | US$33.95m |
Revenue (TTM) | US$199.89m |
52.9x
P/E Ratio9.0x
P/S RatioIs LMAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LMAT income statement (TTM) | |
---|---|
Revenue | US$199.89m |
Cost of Revenue | US$67.06m |
Gross Profit | US$132.83m |
Other Expenses | US$98.88m |
Earnings | US$33.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.51 |
Gross Margin | 66.45% |
Net Profit Margin | 16.99% |
Debt/Equity Ratio | 0% |
How did LMAT perform over the long term?
See historical performance and comparison